Patents by Inventor Matthieu BROUSSAS

Matthieu BROUSSAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220105195
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: November 15, 2021
    Publication date: April 7, 2022
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-François HAEUW, Marie LAMOTHE
  • Publication number: 20200270352
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 27, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT, Marie LAMOTHE
  • Publication number: 20190269788
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: April 16, 2019
    Publication date: September 5, 2019
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-François HAEUW, Marie LAMOTHE
  • Publication number: 20190202901
    Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
    Type: Application
    Filed: October 26, 2016
    Publication date: July 4, 2019
    Inventors: Alexandra JOUHANNEAUD, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Thierry CHAMPION, Robert ALAIN, Jean-François HAEUW, Ian RILATT, Michel PEREZ
  • Publication number: 20180228915
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 16, 2018
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW
  • Publication number: 20170043032
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW